Boromycin has Rapid-Onset Antibiotic Activity Against Asexual and Sexual Blood Stages of Plasmodium falciparum

Laís Pessanha de Carvalho 1, Sara Groeger-Otero 1, Andrea Kreidenweiss 1,2,3, Peter G. Kremsner 1,2,3, Benjamin Mordmüller 1,2,3,4 and Jana Held 1,2,3*

1 Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany, 2 Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon, 3 German Center for Infection Research (DZIF), partner site Tübingen, Tübingen, Germany, 4 Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, Netherlands

Boromycin is a boron-containing macrolide antibiotic produced by Streptomyces antibioticus with potent activity against certain viruses, Gram-positive bacteria and protozoan parasites. Most antimalarial antibiotics affect plasmodial organelles of prokaryotic origin and have a relatively slow onset of action. They are used for malaria prophylaxis and for the treatment of malaria when combined to a fast-acting drug. Despite the success of artemisinin combination therapies, the current gold standard treatment, new alternatives are constantly needed due to the ability of malaria parasites to become resistant to almost all drugs that are in heavy clinical use. In vitro antiplasmodial activity screens of tetracyclines (omadacycline, sarecycline, methacycline, demeclocycline, lymecycline, meclocycline), macrolides (oleandomycin, boromycin, josamycin, troleandomycin), and control drugs (chloroquine, clindamycin, doxycycline, minocycline, eravacycline) revealed boromycin as highly potent against Plasmodium falciparum and the zoonotic Plasmodium knowlesi. In contrast to tetracyclines, boromycin rapidly killed asexual stages of both Plasmodium species already at low concentrations (~1 nM) including multidrug resistant P. falciparum strains (Dd2, K1, 7G8). In addition, boromycin was active against P. falciparum stage V gametocytes at a low nanomolar range (IC50: 8.5 ± 3.6 nM). Assessment of the mode of action excluded the apicoplast as the main target. Although there was an ionophoric activity on potassium channels, the effect was too low to explain the drug’s antiplasmodial activity. Boromycin is a promising antimalarial candidate with activity against multiple life cycle stages of the parasite.

Keywords: antibiotics, Plasmodium falciparum, Plasmodium knowlesi, tetracyclines, delayed death effect, boromycin, macrolides
1 INTRODUCTION

Malaria remains one of the world’s most serious public health problems, especially in tropical and subtropical areas, with approximately 241 million cases and 627,000 deaths in 2020 (World Health Organization, 2021). Intracellular parasites of the genus Plasmodium cause the disease, and among the six species that can infect humans P. falciparum, P. vivax, P. malariae, P. ovale wallikeri, P. ovale curtisi, and the zoonotic species P. knowlesi (Rutledge et al., 2017; Grignard et al., 2019), P. falciparum is the most virulent (World Health Organization, 2021). P. knowlesi, described originally as a simian parasite, was recognized in 2000 as a zoonotic species that can infect humans (White, 2008). Although P. knowlesi occurs mainly in Malaysia, counting 13,612 malaria cases between 2017 to 2020 (Hu et al., 2021), it can cause severe malaria in humans (Amir et al., 2018) and is phylogenetically closer to other human pathogenic Plasmodium species (P. malariae, P. vivax, and P. ovale species) than P. falciparum (Rutledge et al., 2017; van Schalkwyk et al., 2019).

Plasmodium parasites have a complex life cycle that includes mosquito and vertebrate hosts (Siciliano and Alano, 2015). Clinical symptoms of malaria appear during the replication of parasites in the erythrocytic cycle (lasting approximately 24 h for P. knowlesi and 48 h for P. falciparum) in the human host (van Biljon et al., 2018). These symptoms can develop into life-threatening complications such as severe anemia, liver and kidney failure and cerebral malaria if not treated properly (Milner et al., 2014). During each replication cycle, a small number of asexual parasites starts a different genetic program and develops into the transmissible sexual form, named gametocytes (Portugaliza et al., 2020). Gametocytes are non-dividing parasite stages with low metabolic activity whose immature stages are hidden in the bone marrow while the mature stage (stage V) circulates in the blood stream (Gardiner and Trenholme, 2015).

Currently, the mainstay P. falciparum malaria treatments are artemisinin-based combination therapies (ACT) (World Health Organization, 2021). Artemisinin and its derivatives are fast-acting and rapidly reduce the asexual parasite load but have a short half-life (2-4 h for artemisinin and <1 h for artesunate) (Benakis et al., 1997). They are combined to a slow-acting partner drug with longer half-life to clear remaining parasites, and to protect artemisinin against resistances. Nonetheless, reports of P. falciparum with delayed clearance after artesunate or ACT treatment are accumulating, especially from the Greater Mekong Region where resistances to the partner drugs are also present (Pluim et al., 2019; WWARN K13 Genotype-Phenotype Study Group, 2019). More recently first reports of kelch13 mutated parasites with a slow clearance have also appeared from Africa (Balikagala et al., 2021). This poses a threat to the existing malaria treatment options (Strainer et al., 2015; Nsanzabana, 2019). In addition, the current ACT drugs are inactive against mature P. falciparum gametocytes (stage IV and V). In low transmission areas is recommended to give additionally a single dose of primaquine, except in children younger than six months, pregnant and breastfeeding women with infants younger than six months, to prevent transmission of the parasite, but these recommendations are so far not strictly followed in all areas (World Health Organization, 2021).

The interest in using antibiotics for malaria treatment appeared due to the emergence of resistant parasites to the former mainstay drug chloroquine. Tetracyclines were the first antibiotics used to treat uncomplicated malaria, dating back to the 1950s (Imboden et al., 1950; Grande et al., 1956). Currently, doxycycline and the combination of sulfadoxine-pyrimethamine are used for malaria prevention of travelers and risk groups in malaria-endemic regions, respectively. In addition, clindamycin combined with quinine is used to treat pregnant women during the first trimester or combined with artesunate or quinine to treat uncomplicated malaria when an ACT is unavailable (World Health Organization, 2021).

Tetracyclines and macrolides, both naturally produced by Streptomyces, have shown promising antiplasmodial activities as reviewed before (Gaillard et al., 2015; Gaillard et al., 2016; de Carvalho et al., 2021). Most antibiotics with antiplasmodial activity target the apicoplast; a plastid-like organelle derived from endosymbiotic bacteria responsible for the biosynthesis of isoprenoid precursors (Yeh and DeRisi, 2011). Antibiotics can be fast or slow-acting drugs, depending on whether they target the treated parasites or act on their progeny, causing the so-called delayed death effect (Dahl and Rosenthal, 2007). Commonly, tetracyclines belong to the latter group (Gaillard et al., 2015; de Carvalho et al., 2021), and novel tetracyclines have shown superior antiplasmodial activity (e.g. eravacycline and tigecycline IC50s at 14 and 38 nM, respectively (Held et al., 2010; Koehne et al., 2021) versus doxycycline and tetracycline IC50s at 241 and 340 nM, respectively) (Koehne et al., 2021). Some macrolides such as ivermectin (Mendes et al., 2017; de Carvalho et al., 2019), borrelidin (Otoguro et al., 2003; Ishiyama et al., 2011), and kitasamycin (also called leucomycin) (Ekland et al., 2011) had a fast/first cycle in vitro growth inhibitory activity against P. falciparum (IC50 values of ~ 100 nM, 1.8 nM and 50 nM, respectively). However, the molecular targets of these agents in Plasmodium species are not known.

This study aimed to identify antibiotics that are potent and fast acting against P. falciparum. Therefore, we evaluated the antiplasmodial effect of two recently marketed tetracyclines, named sarecycline, and omadacycline and some “old” tetracyclines in clinical use named demeclocycline, meclocycline, lymecycline, clortetracycline and methacycline (Figure 1). In addition, the macrolides oleandomycin, troleandomycin, josamycin, and boromycin were evaluated (Figure 2). Tetracyclines with known antiplasmodial activity were used as controls. We identified boromycin to be a highly active and fast acting antibiotic. Boromycin is a polyether-macrolide antibiotic produced by Streptomyces antibioticus and was the first boron-containing compound found in nature (Dunitz et al., 1971). Previous studies showed a potent effect of boromycin against Gram-positive bacteria, HIV virus and protozoan parasites (Kohn et al., 1996; Moreira et al., 2016; Abenoja et al., 2021). Due to its low nanomolar activity in our screening, we further assessed its antiplasmodial profile also including transmission stages and investigated whether its
FIGURE 1 | Chemical structures of tetracyclines tested in this study.
potential mode of action involves the apicoplast as described for antibiotics in general (Dahl and Rosenthal, 2007) or ionophoric activity on potassium channels as shown before for boromycin (Moreira et al., 2016). In addition, we evaluated its in vitro activity against another *Plasmodium* species (*P. knowlesi*).

2 MATERIALS AND METHODS

2.1 Chemicals

All tested drugs were first dissolved in their respective solvents and subsequently further diluted in complete culture medium to
have the desired final concentration (Supplementary Table 1 and Supplementary Information Figures 1, 2).

2.2 Parasite In Vitro Culture

2.2.1 Plasmodium Asexual Stages

*P. falciparum* laboratory strains 3D7 (chloroquine-sensitive, provided by BEI resources, MRA-102), Dd2 (multidrug-resistant, provided by BEI resources, MRA-150), K1 (multidrug-resistant, provided by BEI resources, MRA-159), 7G8 (chloroquine resistant, provided by BEI resources, MRA-154) and NF-54 (chloroquine sensitive, provided by Sanaria, a vigorous gametocyte producer), and *P. knowlesi* laboratory strain A1-H.1 (kindly provided by Robert Moon of LSHTM, London, UK under a MTA by the Francis Crick institute) were cultivated in *vitro* as described before (Moon et al., 2013; de Carvalho et al., 2019). Briefly, the parasites were maintained in complete culture medium consisting of RPMI-1640 (Sigma-Aldrich) supplemented with 1 M N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid (HEPES) solution (2.4% v/v) (Sigma-Aldrich), 200 mM L-glutamine (Gibco), 50 µg/ml gentamicin (Gibco), and 10% of AlbuMax II solution containing RPMI, HEPES, NaHCO₃, D-Glucose, hypoxanthine and 50 g/l of AlbuMax II (0.5% wt/vol in culture medium) at 2.5% hematocrit. The cultures were maintained at 5% CO₂, 5% O₂, at 37°C, with a change of medium every two days. *P. falciparum* parasites were synchronized by magnetic column separation prior to the assays (Ribaut et al., 2008). *P. knowlesi* was cultivated as described for *P. falciparum*, with minor modifications. Parasites were cultivated in complete culture medium as detailed above supplemented with 5% human AB serum. Shortly before the growth inhibition assays, *P. knowlesi* were synchronized by density centrifugation with Nycodenz solution (Progen) to recover mature schizonts as described before (van Schalkwyk et al., 2017). The Nycodenz solution was prepared according to the manufacturer’s instruction and kept protected from the light at 4°C and warmed before using.

The asexual growth inhibition assays were performed with 3D7 and A1-H.1, while NF-54 was used for gametocyte assays. 

2.2.2 *P. falciparum* Sexual Stages

*P. falciparum* gametocyte culture was performed as described previously (de Carvalho et al., 2019) with minor modifications. The gametocyte culture was initiated with synchronized ring-stage NF54 parasites at 6% hematocrit and 0.3% parasitemia. Complete culture medium (as described above) was supplemented with 5% human serum and changed daily without parasite dilution for 14 days. The medium was doubled when parasitemia reached 5%, and 50-mM N-acetyl-d-glucosamine (MP Biomedicals GmbH) was added between day 11 and day 14 to remove asexual stages. On day 15, mature gametocytes were purified with a Nycodenz and magnetic column separation (MACS) to remove erythrocytes and concentrate the gametocyte population.

2.3 Growth Inhibition Assays With Asexual Parasites

Growth inhibition assays of asexual stages of *P. falciparum* were performed as described before (Noedl et al., 2005). Briefly, the drugs (Supplementary Table 1) were distributed in a 3-fold serial dilution in 96-well plates. The highest concentration of the solvent (<0.1%) did not interfere with parasite growth. Synchronized ring-stage parasites were diluted to a parasitemia of 0.05% with O Rh+ erythrocytes in complete culture medium and seeded at a hematocrit of 1.5% in a total volume of 225 µl per well. Plates were subsequently incubated at 5% CO₂, 5% O₂, at 37°C before the plates were frozen and thawed three times. The growth inhibition of *P. falciparum* was measured through an enzyme-linked immunosorbent assay (ELISA) for histidine-rich protein 2 (HRP2) using a microplate reader (CLARIOstar BMG Labtech) (excitation filter: 450 nm).

Growth inhibition assays with *P. knowlesi* were performed as described previously with minor modifications (van Schalkwyk et al., 2019). Briefly, boromycin and chloroquine were distributed in a 3-fold serial dilution in 96-well plates. Synchronized ring-stage parasites were diluted to a parasitemia of 0.5% (a higher parasitemia compared to the HRP2 based assay is needed due to the differences in the limit of detection and therefore optimal assay conditions) with O Rh+ erythrocytes and subsequently seeded at a hematocrit of 2% and complete culture medium without human AB serum but double (20%) AlbuMax II solution in a total volume of 225 µl per well. The growth inhibition of *P. knowlesi* was measured with SYBR Green-I (ThermoFisher) using CLARIOstar (BMG Labtech) (490 nm excitation filter) as HRP2 is not present in this species. For comparison, growth inhibition of boromycin and chloroquine – treated *P. falciparum* was measured using the same methodology.

*P. falciparum* was incubated with the drugs for 3 and 6 days to assess the onset of activity. Both time points were assessed because many antibiotics target only the progeny of the treated parasites, causing a delayed death effect that is measured only after the second replication cycle (after 6 days). Chloroquine and clindamycin were used as positive controls for 3- and 6-day assays, respectively.

To observe the parasite morphology, *P. falciparum* strain 3D7 and Dd2 were incubated with boromycin at 1 nM and for comparison also 3D7 with chloroquine at 8 nM for 6 h for visual observation of drug effect by light microscopy. Thin blood smears were prepared, fixed in 100% methanol for 10 seconds, and stained with Giemsa (Merck) solution (5%) for 20 minutes. The slides were washed and observed under a Leica DMBL microscope, and pictures were taken using a ProgRes C10 camera and software (Jenoptik), at 100X magnification. Three biological replicates were prepared.

2.4 In Vitro Activity Against Mature Gametocytes of *P. falciparum*

Drug sensitivity assays against mature (stage V) *P. falciparum* gametocytes were performed as described previously (Lelièvre et al., 2012; de Carvalho et al., 2019). Briefly, the drugs were precoated in a 3-fold dilution in 96-well plates. The concentration of the solvent did not interfere with parasite growth. Epoxomicin and methylene blue (Supplementary Table 1) were used as positive control. Subsequently, the previously purified mature gametocytes were seeded to the
plates (50,000 gametocytes/well) and incubated at 37°C in 5% CO₂ and 5% O₂. After 48 h, the ATP production was measured by the BacTiterGlo assay (Promega), according to the manufacturer’s instructions. Finally, the results were quantified using a luminometer (LUmio; AutoBio). In addition, to visually inspect the effect of boromycin on gametocytes thin blood smears of untreated and boromycin (8 nM) and epoxomicin (15 nM) - treated gametocytes (50,000 gametocytes/well), were prepared, fixed in 100% methanol for 10 seconds, and stained with Giemsa (Merck) solution (5%) for 20 minutes. The slides were washed and observed under a Leica DMBL microscope, and pictures were taken using a ProgRes C10 camera and software (Jenoptik), at 100X magnification.

2.5 Cytotoxicity Assay
HepG2 cells (obtained from ATCC; HB-8065), a human hepatocyte carcinoma cell line, were maintained in DMEM medium (Sigma-Aldrich) supplemented with 10% of inactivated foetal bovine serum (Sigma-Aldrich), 200 mM L-glutamine (Gibco), 12 mL of HEPES buffer (Gibco), and 50 µg/ml penicillin/streptomycin solution (Gibco). Trypsin (Gibco) was used to detach the cells when they reached a semi-confluent layer.

Cytotoxicity was evaluated using the neutral red assay as described previously (Mishra et al., 2021). Briefly, 300,000 cells were seeded in supplemented Dulbecco’s Modified Eagle’s Medium (DMEM) medium as described above to 96-well plates. After 24 hours, the cells were incubated with a twofold serial dilution of the respective drug diluted in supplemented DMEM medium for an additional 24 hours. The highest concentration of the solvent (<1%) did not interfere with cell viability. Subsequently, the drug-containing medium was replaced by a supplemented DMEM medium with 1.5% of neutral red, and the cells were incubated for an additional 3 h at 37°C. Cells were then washed with phosphate buffered saline (pH 7.2), and 100 µL of freshly prepared lysing buffer (50% methanol, 49% distilled water, and 1% acetic acid) were added to the plates. Subsequently, the cells were shaken for 10 min and the absorption was measured at a wavelength of 540 nm using CLARIOstar (BMG Labtech).

2.6 Isopentenyl Pyrophosphate Trilithium Salt (IPP) Rescue Assay
Growth inhibition assays were prepared as described in section Parasite In Vitro Culture with modifications to assess the specificity of boromycin for the inhibition of the isoprenoid precursor biosynthetic pathway (MEP/DOXP/non-mevalonate pathway) found in the apicoplast (Uddin et al., 2018). Briefly, the parasites (P. falciparum strain 3D7) were incubated with boromycin and clindamycin (positive control) and supplemented with IPP (Sigma) at 200 µM for 6 days as described before (Uddin et al., 2018). Since biosynthesis of isoprenoid precursors is the only required function of the apicoplast, supplementation with IPP can rescue treated parasites if the apicoplast is the main target of the drug (Uddin et al., 2018). The assay was done with and without IPP supplementation on the same plate and results were directly compared.

2.7 Ionophoric Activity Assay
Previously, boromycin was described to act as a potassium ionophore in Bacillus subtilis and Mycobacterium tuberculosis (Pache and Zaehner, 1969a; Moreira et al., 2016). So herein, growth inhibition assays complemented with KCl or MgCl₂ (negative control) were performed to evaluate if this is also the case in P. falciparum. To define a subtoxic concentration of MgCl₂ and KCl for P. falciparum a standard growth inhibition assays with serial dilutions of these compounds were performed as described in section Parasite In Vitro Culture. The concentration of 220 µg/mL was chosen as no signs of toxicity were seen and first inhibitory effects were observed with 440 µg/mL (Supplementary Figure 1) Subsequently, a growth inhibition assay was prepared with a 2-fold dilution of boromycin with the addition of the sub-toxic concentration of either MgCl₂ (Sigma) or KCl (Sigma) to all wells. The assay was run in parallel to a standard growth inhibition assay of boromycin without supplementation of MgCl₂ or KCl as control, and the obtained IC₅₀ values were compared.

2.8 Analysis
All assays were performed at least three times in duplicates. Individual IC₅₀ values were determined by nonlinear regression analysis of log concentration-response curves, using the drc v3.0.1 package (Ritz and Streibig, 2005) of R v4.1.2 (R Core Team, 2014). Mean IC₅₀ values and standard deviations (SDs) were calculated for each growth inhibition assay using Excel. The chemical structures of the drugs were drawn using ChemDraw 19.0. The graphical presentations and statistical analyses (unpaired t-test) were done with GraphPad Prism v8.

3 RESULTS

3.1 Activity of Antibiotics Against Asexual Stages of P. falciparum and P. knowlesi
P. falciparum was exposed to 15 antibiotics (tetracyclines, macrolides) and chloroquine (control drug) for 3 and for 6 days. This allowed to assess the drug’s inhibitory effect on the first and second parasite replication cycle, respectively (see results in Table 1), that indicates a fast or slow onset of antiplasmodial activity of the antibiotics.

None of the tetracyclines evaluated in this study showed a pronounced activity (in the nanomolar range) in the 3-day assay against P. falciparum, but had some delayed activity after 6 days of drug exposure (Table 1). Chlortetracycline, methacycline and lymecycline were still poorly active after 6 days. The first-time tested drugs against P. falciparum demeclocycline, sarecycline, omadacycline and the already previously tested drugs/controls doxycycline, minocycline, and eravacycline were active in the nanomolar range against both species after 6 days (Table 1). Boromycin was highly active against P. falciparum at an IC₅₀ of 1.0 nM after 3 days of incubation (Table 1). To further characterize its antiplasmodial activity, boromycin was also
assessed against *P. knowlesi* and its pronounced activity was confirmed there (Table 1).

### 3.2 Cytotoxicity of Boromycin Against Human Cells

Boromycin was cytotoxic at millimolar concentrations against human HepG2 cells with a selectivity index (SI) higher than 200,000. (Table 2). Chloroquine was used as comparator and was more cytotoxic than boromycin.

### 3.3 Characterization of the Antiplasmodial Activity of Boromycin

#### 3.3.1 Activity of Boromycin Against Asexual Stages of *P. falciparum* Chloroquine-Resistant Strains

Different drug resistant strains of *P. falciparum* (Dd2, K1 and 7G8) were incubated with boromycin for 3 days to assess the potential of cross-resistance. Results were comparable to activities against 3D7 with IC₅₀ values in the picomolar range, and no cross-resistance to boromycin by these parasite lines was seen (Table 3). When investigating the morphological effect of the drug treatment on the parasite, untreated *P. falciparum* parasites of the strain 3D7 (Figure 3A) showed the usual ring shape, while boromycin-treated ring-stages (Figure 3B), as well as trophozoites and schizonts (Supplementary Figure 2) showed the same pyknotic appearance after boromycin incubation at 1 nM for 6 h. In addition, the same fast effect and morphological changes were also induced in the chloroquine resistant strain Dd2 (Figure 3C).

#### 3.3.2 Activity of Boromycin Against Mature Gametocytes

Mature *P. falciparum* gametocytes (stage IV and V) were incubated with a serial dilution of boromycin for 48 h. Afterwards, ATP production was quantified to evaluate the gametocytocidal effect (Figure 4A). The results revealed that boromycin was highly active (IC₅₀ at 8.5 ± 3.6 nM), similarly active as the positive comparator epoxomicin (15.2 ± 3.4 nM) and more active than methylene blue (284 ± 35 nM). When observed microscopically, untreated gametocytes displayed their usual elongated shape with rounded edges (Figure 4A), but both boromycin (Figures 4B, C) and epoxomicin – treated (Figures 4C, D) parasites showed thinner body and edges, and intracellular disorganization. The length was not affected in epoxomicin-treated gametocytes, resulting in a needle-like shape, while boromycin-treated gametocytes presented a smaller appearance.

#### 3.3.3 Activity of Boromycin on the Apicoplast

*P. falciparum* parasites were incubated with boromycin supplemented with IPP for 6 days to assess whether boromycin targets the apicoplast as described for many antibiotics;

---

**Table 1 | Activity of antibiotics against *P. falciparum* strain 3D7 after 3 and 6 days of incubation and *P. knowlesi* strain A1-H.1 after 3 days.**

| Classe     | Drug               | *Plasmodium falciparum* (3D7) and *P. knowlesi* (A1-H.1) (IC₅₀ in nM) | Fold differences between 3 and 6 days |
|------------|--------------------|------------------------------------------------------------------------|---------------------------------------|
|            |                    | 3 day-assay | 6 day-assay | 3D7 | A1-H.1 | 3D7 |
| Tetracyclines | Chlorotetracycline  | > 18000     | > 18000     | NA  |        |
|             | Methacycline       | > 18000     | 3719 ± 3134 | NA  |        |
|             | Lymecycline        | > 18000     | 1124 ± 247  | NA  |        |
|             | Demeclocycline     | > 18000     | 410.1 ± 165 | NA  |        |
|             | Meclocycline       | > 18000     | 291.7 ± 41  | NA  |        |
|             | Sarecycline        | 13378.9 ± 1053 | 244.1 ± 136 | NA  |        |
|             | Omadacycline       | 8443 ± 618  | 247.8 ± 109 | 34  |
| Macrolides  | Oleandomycin       | 8186 ± 3851 | > 18000     | NA  |        |
|             | Trokamycin         | > 18000     | > 18000     | NA  |        |
|             | Josamycin          | 0.9 ± 0.1   | 1.3 ± 0.2*  | 5.9 ± 3.5* | 0 |
|             | Boromycin          | > 18000     | 387.8 ± 185 | NA  |        |
| Controls    | Minocycline        | 9393 ± 4354 | 83.5 ± 25   | 113 |
|             | Eravacycline       | 2514 ± 550  | 5.1 ± 1.1   | 502 |
|             | Clindamycin        | > 18000     | 5.9 ± 3.4   | NA  |        |
|             | Doxycycline        | 9579 ± 2756 | 385.7 ± 292 | 24  |
|             | Chloroquine        | 8.4 ± 4.9   | 21.1 ± 11*  | 14.5 ± 9.3* | 0 |

*Measured by SYBR Green-I.
All experiments have been done at least 3 times in duplicate.

**Table 2 | Cytotoxicity of boromycin and the comparator chloroquine against HepG2 cells and calculated selectivity index.**

| IC₅₀ (µM) in HepG2 cells | SI 3D7* | SI A1-H.1* |
|--------------------------|---------|-------------|
| Boromycin                | 1250.5 ± 230 | 1,388,000 | 211,864 |
| Chloroquine              | 153.4 ± 52.9 | 18,214 | 10,551 |

*IC₅₀ 3-day assays; SI: selectivity index calculated by IC₅₀ HepG2/IC₅₀ Plasmodium species.
All experiments have been done at least 3 times in duplicate.
Clindamycin was used as a positive control. At the same time, a standard growth inhibition assay without IPP was carried out as a comparator. As expected, clindamycin-treated parasites could be rescued by the supplementation with IPP, but the IC\textsubscript{50} values for boromycin remained similar at low nanomolar concentrations for both conditions (Table 4), suggesting that this drug effect cannot be rescued by IPP and has a different target from the apicoplast (Figure 5).

### 3.3.4 Ionophoric Activity of Boromycin

P. falciparum parasites were incubated with a serial dilution of boromycin, and chloroquine (control) with or without supplementation of 220 µg/mL of MgCl\textsubscript{2} or KCl, for 3 days to assess whether boromycin has the ionophoric activity on P. falciparum as described for Mycobacterium and Bacillus subtilis (Abenoja et al., 2021) (Table 5). Boromycin and chloroquine displayed the expected IC\textsubscript{50} value, the supplementation of KCl at

| TABLE 3 | Antiplasmodial activity of boromycin against different P. falciparum chloroquine-resistant strains in comparison to 3D7 after 3 days of incubation. |
|---|---|---|---|---|
| | 3D7 | Dd2 | K1 | 7G8 |
| Boromycin | 0.9 ± 0.1 | 0.6 ± 0.4 | 0.7 ± 0.1 | 0.4 ± 0.07 |
| Chloroquine | 8.4 ± 4.9 | 302 ± 119 | 401.4 ± 28.3 | 303.6 ± 18.2 |

All experiments have been done at least 3 times in duplicate.
220 µg/mL increased IC₅₀ of boromycin by 3-fold, while no difference was observed for chloroquine. On the other hand, the incubation with boromycin or chloroquine in the presence of MgCl₂ led to a 3-5-fold decrease in the respective IC₅₀s.

4 DISCUSSION

Antibiotics for malaria treatment have been investigated since the middle of the last century, with tetracyclines playing a central role. In recent years, macrolides have also been particularly studied as antimalarials (Gaillard et al., 2015; Gaillard et al., 2016a; Gaillard et al., 2016b). Although the delayed death effect caused by most antibiotics limits their use as first-line chemotherapy, some antibiotics such as doxycycline, clindamycin, and the combination sulfadoxine-pyrimethamine (that does not display the delayed activity) are recommended as prophylaxis or treatment in certain populations (World Health Organization, 2021). The need for new alternative therapies, along with the limited investments in drug discovery to treat malaria, make drug repurposing a worthy alternative. Herein, the in vitro antiplasmodial activity of tetracyclines and macrolides not previously tested against Plasmodia along with comparator drugs were evaluated against blood-stages of *P. falciparum* revealing boromycin, as a potent antiplasmodial drug with a fast/first cycle activity that we assessed further.

All experiments have been done at least 3 times in duplicate.
Food and Drug Administration, 2021) showed comparable activity to doxycycline. None of the newly tested tetracyclines achieved the activity of the next generation tetracyclines tigecycline (Held et al., 2010) and eravacycline (Koehne et al., 2021) that suggested that modifications at the C9 position on the D ring that circumvents the ribosomal protection resistance mechanism found in bacteria could be beneficial for the activity against Plasmodia. However, the structurally similar omadacycline did not show this improved activity. In a similar way, differences in activities for these three antibiotics were also seen for rickettsia species (Quade et al., 2021). The delayed death effect was also shown by the macrolide josamycin suggesting that the apicoplast could be the target of this drug. The tetracyclines chlortetracycline, methacycline, lymecycline, and the macrolides troleandomycin and oleandomycin were only poorly active with IC50 in the micromolar range. Whereas the macrolide boromycin showed a fast onset of activity at a single-digit nanomolar concentration against both Plasmodium species.

*P. falciparum* is undoubtedly responsible for most of the malaria burden, especially for most of the malaria deaths, which justifies to mainly tailor treatments to this malaria species. However, there are five additional *Plasmodium* species responsible for malaria in humans and when elimination of malaria is the aim, all these species must be targeted. Until recently, *P. falciparum* was the only option for drug screening in vitro because the other human malaria parasites could not be kept in continuous in vitro culture (Mehlotra et al., 2017; van Schalkwyk et al., 2019). However, now *P. knowlesi* has been adapted for in vitro culture and its inclusion in drug screenings could give additional information on antiplasmodial activities of compounds as it is phylogenetically closer to the other human *Plasmodium* species (Rutledge et al., 2017; van Schalkwyk et al., 2019). Even though previous studies have claimed that most antiplasmodial compounds are equipotent against *P. falciparum* and *P. knowlesi* (Moon et al., 2013; Fatih et al., 2013), recent studies have reported different susceptibility profiles (van Schalkwyk et al., 2021) especially for some novel drugs in development. *P. knowlesi* was described as less susceptible to inhibitors of the dihydrofolate reductase, dihydroorotate dehydrogenase (van Schalkwyk et al., 2017), and ATP4 (van Schalkwyk et al., 2019). Herein, we also observed that boromycin was very potent against both species, *P. knowlesi* was slightly less vulnerable than *P. falciparum*, with a 4.5-fold higher IC50.

The most promising antibiotic from our screening was the macrolide boromycin. Boromycin was isolated from a *Streptomyces antibioticus* found in a soil sample from Ivory coast and was first described in 1967 (Hütter et al., 1967; Pache and Zaehner, 1969b). It has a potent effect against Gram-positive bacteria in vitro (Moreira et al., 2016), and it was shown to be active against HIV (Kohno et al., 1996), *Babesia* (Hütter et al., 1967) and some other pathogens (de Carvalho et al., 2019). Its antiplasmodial activity was already once described in a patent filed in the US in 1973 where its activity in the malaria models of *P. berghei* in mice (ED50: 2.2 mg/kg) and *P. gallinaceum* in birds (ED50: ~ 7 mg/kg) is given (Prelog et al., 1973). Additionally, its in vitro activity against *P. falciparum* strain K1 (chloroquine – resistant) and PCR3 (chloroquine – sensitive) was described to be 39 and 40 nM, respectively (Tsutsui et al., 2010). In the same study, only a low selectivity index against MRC-5 cells (~12) was described, but a 97.9% parasite reduction was observed when *P. berghesi* – infected mice were treated p.o at 10 mg/kg according to Peter’s test. However, no description of the evaluation of its gametocytocidal activity and stage specific effect could be identified by us.

In our investigation, boromycin showed a high activity and a fast onset of action, a desired property of antimalarials to quickly reduce parasite load and avoid the disease progression to the severe form. It also showed an excellent selectivity index against HepG2 cells. This favorable toxicity profile was also confirmed previously (Moreira et al., 2016), and the LD50 in mice is given as 180 mg/kg (Klingel, 1980). These results encouraged a more detailed investigation of the antiplasmodial activity of boromycin.

Boromycin’s in vitro activity against laboratory strains showed potent activity as it was active at low nanomolar and even at picomolar concentrations. No cross-resistance with the tested chloroquine/multi-resistant strains (DD2, 7G8, and K1) was seen as the IC50 values were in same range as for the drug sensitive strain 3D7, suggesting that is not affected by the common resistance mechanisms (Ding et al., 2012). Morphologically, ring stage parasites showed a pyknotic appearance after 6 h treatment with boromycin at 1 nM, suggesting that it leads to a rapid death. We additionally evaluated the activity of boromycin against mature gametocytes and could see a very potent activity superior to the positive control methylene blue, similarly active as the proteasome inhibitor epoxomicin. Drugs with transmission-blocking activity are of special interest and would be a great asset for controlling and eliminating malaria (Sinden, 2017; Wadi et al., 2019). Currently, primaquine is the only approved drug active against gametocytes (Lin et al., 2017) but its use is restricted mainly due to its haemolysis-inducing effect in patients with glucose-6-phosphate dehydrogenase deficiency (Recht et al., 2018), and additionally it has to be metabolized by a liver enzyme (CYP2D6) to be active. Drugs with multi-stage activities and novel modes of action are especially desired for the next generation of antimalaria (Ding et al., 2012).

The apicoplast is described as the main target of antibiotics that exert the delayed death effect (Dahl and Rosenthal, 2007; Ekland et al., 2011) and the fast-acting antibiotic fosmidomycin (Uddin et al., 2018). Apicomplexa-free parasites can survive and proliferate when the medium is supplemented with IPP (Yeh and DeRisi, 2011), but this did not rescue the boromycin-treated parasites in our assay; therefore, we could rule out the apicoplast as a main target.

The ionophoric activity of boromycin, especially for K+ channels, was firstly described in *Bacillus subtilis* in addition to the impairment of protein, RNA, and DNA synthesis (Pache and Zaehner, 1969a). This ionophoric activity was later confirmed in *Mycobacterium bovis*, where a rapid loss of membrane potential, reduction of intracellular ATP, and leakage of cytoplasmic proteins were induced (Moreira et al., 2016) and the external
addition of a high concentration of KCl (20 mg/mL) decreased boromycin activity from 50% to 10%. To assess whether boromycin acts as a potassium ionophore also in Plasmodium falciparum, parasites were simultaneously incubated with boromycin together with the highest non-toxic concentration (220 µg/mL) of KCl or MgCl2 (negative control). We could not incubate Plasmodium parasites at a similar high ion concentration as in the Mycobacterium experiments, as this concentration was toxic to the parasites. We identified a three-fold IC50 increase with the addition of KCl. However, it is most probably not the primary mode of action, as the activity remained in the low nanomolar range. On the other hand, the boromycin IC50 decreased with addition of MgCl2; this was also seen for chloroquine, an effect that was described before (Hess et al., 1995). Recently, boromycin was shown to decrease intracellular multiplication of both Toxoplasma gondii and Cryptosporidium parvum (Abenoja et al., 2021), but the potential target in these parasites was not further investigated.

In conclusion, we presented the antiplasmodial activity of different tetracycline and macrolide antibiotics against P. falciparum. The tetracyclines tested here did not show higher in vitro activities than previously tested tetracyclines and all displayed a slow/second cycle onset of action. The macrolide boromycin showed the most noticeable results as a fast-acting drug against both Plasmodium species and P. falciparum mature gametocytes. These results, along with the historical antiparasitic effects of boromycin, suggest that boromycin deserves a deeper investigation as an alternative therapy for diseases caused by apicomplexan parasites, including Plasmodia.

REFERENCES

Abenoja, J., Cotto-Rosario, A., and O’Connor, R. (2021). Boromycin has Potent Anti-Toxoplasma and Anti-Cryptosporidium Activity. Antimicrob. Agents Chemother. 65, e01278–e01220. doi: 10.1128/AAC.01278-20

Amir, A., Cheong, F. W., de Silva, J. R., Liew, J. W. K., and Lau, Y. L. (2018). Plasmodium Knowlesi Malaria: Current Research Perspectives. Infect. Drug Resist. 11, 1145–1155. doi: 10.2147/IDR.S146644

Balkigala, B., Fukuda, N., Ikeda, M., Katuro, O. T., Tachibana, S.-I., Yamauchi, M., et al. (2021). Evidence of Artemisinin-Resistance Malaria in Africa. NEJM 385, 1163–1171. doi: 10.1056/NEJMoai2101746

Benakis, A., Paris, M., Loutan, L., Plessas, C. T., and Plessas, S. T. (1997). Pharmacokinetics of Artemisinin in Artesunate After Oral Administration in Healthy Volunteers. Am. J. Trop. Med. Hyg. 56, 17–23. doi: 10.4269/ajtmh.1997.56.17

Dahl, E. L., and Rosenhal, P. J. (2007). Multiple Antibiotics Exert Delayed Effects Against the Plasmodium Falciparum Apicoplast. Antimicrob. Agents Chemother. 51, 3485–3490. doi: 10.1128/AAC.00527-07

de Carvalho, L. P., Kreidenweiss, A., and Held, J. (2011). Drug Repurposing: A Review of Old and New Antibiotics for the Treatment of Malaria: Identifying Antibiotics With a Fast Onset of Antiplasmodial Action. Molecules 26, 2304. doi: 10.3390/molecules26082304

de Carvalho, L. P., Sandri, T. L., de Melo, E. J. T., Fendel, R., Kremsner, P. G., Mordmüller, B., et al. (2019). Invermectin Impairs the Development of Sexual and Asexual Stages of Plasmodium Falciparum In Vitro. Antimicrob. Agents Chemother. 63, e00085–e00019. doi: 10.1128/AAC.00085-19

Ding, X. C., Ubben, D., and Wells, T. N. C. (2012). A Framework for Assessing the Risk of Resistance for Anti-Malarials in Development. Malar. J. 11, 292–303. doi: 10.1186/1747-2875-11-292

Dunitez, J. D., Hawley, D. M., Mäkel, D., White, D. N. J., Berlin, Y., Marusich, R., et al. (1971). Structure of Boromycin. Helv. Chim. Acta 54, 1709–1713. doi: 10.1002/hlca.19710540624

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

JH and LPC designed the study, experiments were performed by SG-O. JH, LPC, and SG-O analyzed the data, all authors contributed to interpretation of the data. The first draft of the manuscript was written by LPC. All authors commented and contributed to the article and approved the final version of the manuscript.

ACKNOWLEDGMENTS

We acknowledge support by Open Access Publishing Fund of University of Tübingen.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2021.802294/full#supplementary-material

Ekland, E. H., Schneider, J., and Fidock, D. A. (2011). Identifying Apicoplast-Targeting Antimalarials Using High-Throughput Compatible Approaches. FASEB J. 25, 3583–3593. doi: 10.1096/fj.11-187401

Fathi, F. A., Staines, H. M., Siner, A., Ahmed, M. A., Woon, L. C., Pasini, E. M., et al. (2013). Susceptibility of Human Plasmodium Knowlesi Infections to Anti-Malarials. Malar. J. 12, 1–7. doi: 10.1186/1475-2875-12-425

Gaillard, T., Dormoi, J., Madamet, M., and Pradines, B. (2016a). Macrolides and Associated Antibiotics Based on Similar Mechanism of Action Like Lincosamides in Malaria. Malar. J. 15, 1–11. doi: 10.1186/s12936-016-1114-z

Gaillard, T., Madamet, M., and Pradines, B. (2015). Tetracyclines in Malaria. Malar. J. 14, 445. doi: 10.1186/s12936-015-0980-0

Gaillard, T., Madamet, M., Tsombeng, F. F., Dormoi, J., and Pradines, B. (2016b). Antibiotics in Malaria Therapy: Which Antibiotics Except Tetracyclines and Macrolides may be Used Against Malaria? Malar. J. 15, 1–10. doi: 10.1186/s12936-016-1113-y

Gardiner, D. L., and Trenholme, K. R. (2015). Plasmodium Falciparum Gametocytes: Playing Hide and Seek. Ann. Transl. Med. 3, 45. doi: 10.3978/j.issn.2305-5839.2015.01.23

Grande, E. N., Sanchez, A. R., and Sanchez, F. R. (1956). The Treatment of Malaria With Tetracycline. Antimot. Med. Clin. Ther. 3, 193–196.

Gringard, L., Shah, S., Chua, T. H., William, T., Drakeley, C. J., and Fornace, K. M. (2019). Natural Human Infections With Plasmodium Cynomolgi and Other Malaria Species in an Elimination Setting in Sabah, Malaysia. J. Inf. Dis. 220, 1946–1949. doi: 10.1093/infdis/jiz397

Held, J., Zanger, P., Issifou, S., Kremsner, P. G., and Mordmüller, B. (2010). In Vitro Activity of Tigecycline in Plasmodium Falciparum Culture-Adapted Strains and Clinical Isolates From Gabon. Int. J. Antimicrob. Agents 35, 587–591. doi: 10.1016/j.ijantimicag.2010.02.003

Hess, F. L., Kilian, A., Söllner, W., Nothdurft, H. D., Pröll, S., and Löscher, T. (1995). Plasmodium Falciparum and Plasmodium Berghei: Effect of
Mendes, A. M., Albuquerque, I. S., Machado, M., Pissarra, J., Meireles, P., and Lin, J. T., Lon, C., Spring, M. D., Sok, S., Chann, S., Ittiverakul, M., et al. (2017). 

Kohno, J., Kawahata, T., Otake, T., et al. (1996). 

Klingel, W. (1980). 

Bor in Biologie, Medizin Und Pharmazie: Physiologische 

Frontiers in Cellular and Infection Microbiology | www.frontiersin.org January 2022 | Volume 11 | Article 802294

de Carvalho et al. Antiplasmodial Activity of Boromycin

Moreira, W., Aziz, D. B., and Dick, T. (2016). Boromycin Kills Mycobacterial 

Moon, R. W., Hall, J., Rangkuti, F., Ho, Y. S., Almond, N., Mitchell, G. H., et al. (2014). The Systemic Pathology of Cerebral Malaria in African Children. 

Noedl, H., Bronnert, J., Yingkuen, K., Atmattay, B., Kollaritsch, H., and Fukuda, M. (2015). Simple Histidine-Rich Protein 2 Double-Site Sandwich Enzyme-Linked 

Otguro, K., Ui, H., Ishiyama, A., Kobayashi, M., Ogata, H., Takahashi, Y., et al. (2003). In Vitro and In Vivo Antimalarial Activities of a Non-Glycosidic 18- 

Membered Macrolide Antibiotic, Borrelidin, Against Drug-Resistant Strains of Plasmodia. J. Antibiot. 56, 727–729. doi: 10.7164/antibiotics.56.727

Pache, W., and Zaeher, H. (1969a). Metabolic Products of Microorganisms. Arch. 

Pache, W., and Zaeher, H. (1969b). Stoffwechselprodukte Von Mikroorganismen. Arch. Mikrobiol. 288, 281–288. doi: 10.1007/BF00412060

Pluim, R. W., Imwong, M., Chau, N. H., Hoa, N. T., Thuy-Nhien, N. T., Thanh, N. V., et al. (2019). Determinants of Dihydroartemisinin-Piperaquine Treatment 

van Schalkwyk, D. A., Blasco, B., Davina, N. R., Liew, J. W. K., Amir, A., Lau, Y. L., et al. (2019). Plasmodium Knowlesi Exhibits Distinct In Vitro Drug Susceptibility Profiles From Those of Plasmodium Falciparum. Int. J. Parasitol. Drugs Drug Resist. 9, 93–99. doi: 10.1016/j.jpd.2019.02.004

van Schalkwyk, D. A., Moon, R. W., Blasco, B., and Sutherland, C. J. (2017). Comparison of the Susceptibility of Plasmodium Knowlesi and Plasmodium 

van Schalkwyk, D. A., Moon, R. W., Blasco, B., and Sutherland, C. J. (2017). Comparison of the Susceptibility of Plasmodium Knowlesi and Plasmodium
Falciparum to Antimalarial Agents. *J. Antimicrob. Chemother.* 72, 3051–3058. doi: 10.1093/jac/dkx279

van Schalkwyk, D. A., Moon, R. W., Duffey, M., Leroy, D., and Sutherland, C. J. (2021). *Ex Vivo* Susceptibility to New Antimalarial Agents Differs Among Human-Infecting Plasmodium Species. *Int. J. Parasitol. Drugs Drug Resist.* 17, 5–11. doi: 10.1016/j.ipddr.2021.07.002

Wadi, I., Nath, M., Anvikar, A. R., Singh, P., and Sinha, A. (2019). Recent Advances in Transmission-Blocking Drugs for Malaria Elimination. *Future Med. Chem.* 11, 3047–3088. doi: 10.4155/fmc-2019-0225

White, N. J. (2008). Plasmodium Knowlesi: The Fifth Human Malaria Parasite. *Clin. Infect. Dis.* 15, 172–173. doi: 10.1086/524889

World Health Organization. *Guidelines for Malaria*. Available at: https://www.who.int/publications/i/item/guidelines-for-malaria (Accessed December 10, 2021).

World Health Organization. (2021). *World Malaria Report*. Available at: https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021 (Accessed December 22, 2021).

WWARN K13 Genotype-Phenotype Study Group. (2019). Association of Mutation in the Plasmodium Falciparum Kelch13 Gene (P3D7_1343700) With Parasite Clearance Rates After Artemisinin-Based Treatments – A WWARN Individual Patient Data Meta-Analysis. *BMC Med.* 17, 1. doi: 10.1186/s12887-018-1207-3

Yeh, E., and DeRisi, J. L. (2011). Chemical Rescue of Malaria Parasites Lacking an Apicoplast Defines Organelle Function in Blood-Stage Plasmodium Falciparum. *PloS Biol.* 9, e1001138. doi: 10.1371/journal.pbio.1001138

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 de Carvalho, Groeger-Otero, Kreidenweiss, Kremsner, Mordmüller and Held. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.